Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 33
- Doi Number: 10.1200/jco.2015.33.18_suppl.lba7005
- City: Illinois
- Country: United States Of America
- Dokuz Eylül University Affiliated: Yes